Filing Details

Accession Number:
0000920465-18-000002
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-01-03 21:55:43
Reporting Period:
2017-12-29
Accepted Time:
2018-01-03 21:55:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
920465 La Jolla Pharmaceutical Co LJPC Biological Products, (No Disgnostic Substances) (2836) 330361285
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1589362 L. Laura Douglass C/O La Jolla Pharmaceutical Company,
4550 Towne Centre Court
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-12-29 6,000 $10.84 6,000 No 4 M Direct
Common Stock Acquisiton 2017-12-29 4,000 $6.00 10,000 No 4 M Direct
Common Stock Disposition 2017-12-29 10,000 $32.32 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2017-12-29 6,000 $0.00 6,000 $10.84
Common Stock Stock Option (Right to Buy) Disposition 2017-12-29 4,000 $0.00 4,000 $6.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2024-04-03 No 4 M Direct
14,000 2023-11-21 No 4 M Direct
Footnotes
  1. Represents the average sale price, with individual sale prices ranging from $32.29 to $32.49 per share. The reporting person will provide the Staff of the Securities and Exchange Commission or a shareholder with individual sales price information, if requested.
  2. This option represents a right to purchase a total of 6,000 shares of the Issuer's Common Stock, one third of which shall be fully vested and exercisable on April 3, 2015, with the remaining 4,000 shares vesting quarterly thereafter over the next two years.
  3. These options represent a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one quarter of which shall be fully vested and exercisable on October 14, 2014, with the remaining 13,500 shares vesting monthly thereafter over the next three years in 36 equal increments of 375 shares.